GlobeNews Wire

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical…

7 months ago

NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation – NEOG

NEW ORLEANS, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until…

7 months ago

Atypical AI Debuts ExamJam SAT: Personalized Prep That Feels Like a Human Tutor

San Francisco, CA , Sept. 03, 2025 (GLOBE NEWSWIRE) -- Atypical AI unveils ExamJam SAT, a groundbreaking platform that democratizes…

7 months ago

Ai20x Launches as a Solana-Powered Experiment in Sustainable Crypto Design

Paris, France, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ai20x, a Solana-powered experiment in sustainable crypto design, has launched with the…

7 months ago

Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

September 03, 2025 17:17 ET  | Source: Senseonics Holdings, Inc. CGM commercial operations to transition from Ascensia Diabetes Care to…

7 months ago

Sotera Health Announces Secondary Offering of Common Stock

September 03, 2025 16:57 ET  | Source: Sotera Health Services, LLC CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health…

7 months ago

UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences

September 03, 2025 16:57 ET  | Source: vTv Therapeutics Inc. HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv…

7 months ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

September 02, 2025 21:33 ET  | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics,…

7 months ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from…

7 months ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2025 17:00 ET  | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc.…

7 months ago